Cowen initiated coverage on OmniAb with a new price target
$OABI
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Cowen initiated coverage of OmniAb with a rating of Outperform and set a new price target of $10.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/29/2023 | $6.00 | Outperform | RBC Capital Mkts |
| 4/21/2023 | $8.00 | Buy | The Benchmark Company |
| 4/13/2023 | $10.00 | Buy | Craig Hallum |
| 2/22/2023 | $10.00 | Outperform | Cowen |
| 2/13/2023 | $11.00 | Buy | H.C. Wainwright |
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
First and only transgenic chicken platform engineered to express ultralong CDRH3 domains on a human antibody framework broadens therapeutic opportunities beyond conventional antibodies OmniUltra Virtual Investor Event begins at 5:00 p.m. Eastern time today OmniAb, Inc. (NASDAQ:OABI) announces the launch of its new OmniUltra™ platform, the industry's first and only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics (AET) Conference underway in San Diego. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215018419/en/ OmniUltra is a versa
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches[1]. The global anticancer drug market now values immunotherapies at over 45% of total cancer drug revenues, reflecting investor confidence in technologies that engineer specific biological outcomes[2]. Companies deploying proprietary platforms to target previously undruggable proteins are capturing premium valuations as the sector pivots toward modularity and rapid reuse of validated mechanisms, creating momentum for GT Biopharma, Inc.
OmniAb, Inc. (NASDAQ:OABI) today announced it will hold a virtual investor event to showcase the launch of OmniUltra™ on Monday, December 15, 2025, beginning at 5:00 p.m. Eastern time. The event is expected to last approximately one hour and will include a review of OmniAb's newest technology offering, OmniUltra, the industry's only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework. Management will provide an overview of this innovative and pioneering technology platform, its market use and applications, as well as its strategic importance to the business. Conference Call and Webcast Information What: OmniUltra Launch Virtual Investo
RBC Capital Mkts initiated coverage of OmniAb with a rating of Outperform and set a new price target of $6.00
The Benchmark Company initiated coverage of OmniAb with a rating of Buy and set a new price target of $8.00
Craig Hallum initiated coverage of OmniAb with a rating of Buy and set a new price target of $10.00
144 - OmniAb, Inc. (0001846253) (Subject)
144 - OmniAb, Inc. (0001846253) (Subject)
144 - OmniAb, Inc. (0001846253) (Subject)
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
First and only transgenic chicken platform engineered to express ultralong CDRH3 domains on a human antibody framework broadens therapeutic opportunities beyond conventional antibodies OmniUltra Virtual Investor Event begins at 5:00 p.m. Eastern time today OmniAb, Inc. (NASDAQ:OABI) announces the launch of its new OmniUltra™ platform, the industry's first and only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics (AET) Conference underway in San Diego. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215018419/en/ OmniUltra is a versa
OmniAb, Inc. (NASDAQ:OABI) today announced it will hold a virtual investor event to showcase the launch of OmniUltra™ on Monday, December 15, 2025, beginning at 5:00 p.m. Eastern time. The event is expected to last approximately one hour and will include a review of OmniAb's newest technology offering, OmniUltra, the industry's only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework. Management will provide an overview of this innovative and pioneering technology platform, its market use and applications, as well as its strategic importance to the business. Conference Call and Webcast Information What: OmniUltra Launch Virtual Investo
Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and nine months ended September 30, 2025, and provided operating and partner program updates. "Throughout the third quarter we continued to execute on our strategic initiatives while further demonstrating the value of our proprietary technology platform to a growing base of partners. The number of new program additions so far this year has significantly outpaced last year, bolstering our partnered pipeline and creating potential sources of enduring value within our portfolio. Importantly, OmniAb's innovative technology platform and operational model
OmniAb, Inc. (NASDAQ:OABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial experience including more than 13 years serving in Chief Financial Officer positions, and will serve on OmniAb's Audit Committee as Chair. With this appointment the OmniAb Board returns to seven directors, including five independent directors. "We are delighted Steve has agreed to join the OmniAb Board of Directors and extend a warm welcome," stated John Higgins, OmniAb Board Chair. "Steve's vast financial expertise, technical knowledge and experience leading technology and biotechnology companies will be valuable assets as we grow and expand our
SC 13G/A - OmniAb, Inc. (0001846253) (Subject)
SC 13D/A - OmniAb, Inc. (0001846253) (Subject)